Richard D. Hall

1.6k total citations
54 papers, 809 citations indexed

About

Richard D. Hall is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Richard D. Hall has authored 54 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Surgery. Recurrent topics in Richard D. Hall's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Pancreatic function and diabetes (9 papers). Richard D. Hall is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Pancreatic function and diabetes (9 papers). Richard D. Hall collaborates with scholars based in United States, Germany and Spain. Richard D. Hall's co-authors include Ryan D. Gentzler, Ragini R. Kudchadkar, Lawrence S. Gazda, Daniel Haggstrom, Tri Minh Le, Blair H. Smith, Jhanelle E. Gray, Alberto Chiappori, B.C. Mecrow and A.J. Mitcham and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Richard D. Hall

52 papers receiving 802 citations

Peers

Countries citing papers authored by Richard D. Hall

Since Specialization

Citations

This map shows the geographic impact of Richard D. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Hall more than expected).

Fields of papers citing papers by Richard D. Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Hall. The network helps show where Richard D. Hall may publish in the future.

Co-authorship network of co-authors of Richard D. Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Hall. A scholar is included among the top collaborators of Richard D. Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Hall. Richard D. Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1729 Clinicopathologic Characteristics and Potential Immunotherapeutic Implications of Lung Non-Small Cell Carcinomas with NOTCH Loss-of-Function Mutations 2025 ·Laboratory Investigation ·E. Fred Saunders, Edward B. Stelow, Anne M. Mills, Julie C. Fanburg–Smith, Ryan D. Gentzler, Richard D. Hall, Eli S. Williams	0
2	Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors 2024 ·Current Oncology ·Philip Young, (unknown), (unknown), (unknown), Ryan D. Gentzler, Linda W. Martin, Wendy M. Novicoff, Richard D. Hall	7
3	LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 2023 ·Annals of Oncology ·M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Jacob Sands, Richard D. Hall, Yong Zhang, Hong Zebger‐Gong, (unknown), Isamu Okamoto	34
4	509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 2023 ·Annals of Oncology ·(unknown), Aaron Lisberg, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Jacob Sands, Richard D. Hall, Yong Zhang, Hong Zebger‐Gong, (unknown), Isamu Okamoto	11
5	Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175 2023 ·The Oncologist ·Ryan D. Gentzler, Nisha Mohindra, Shadia I. Jalal, Karen L. Reckamp, Richard D. Hall, Nasser H. Hanna, Young Kwang Chae, Marianna Koczywas, Irene Helenowski, Jyoti D. Patel	3
6	Long‐term efficacy and safety of porcine islet macrobeads in nonimmunosuppressed diabetic cynomolgus macaques 2022 ·Xenotransplantation ·Robert W. Holdcraft, Melanie L. Graham, (unknown), (unknown), (unknown), (unknown), Richard D. Hall, Blair H. Smith, Lawrence S. Gazda	7
7	Racial and Treatment Center Differences on Time to Treatment Initiation for Nonsmall Cell Lung Cancer Patients Receiving Radiation Therapy As an Initial Treatment 2022 ·Health Equity ·(unknown), (unknown), (unknown), Linda W. Martin, Richard D. Hall, James M. Larner, Rajesh Balkrishnan	1
8	OA13.01 S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma 2021 ·Journal of Thoracic Oncology ·Anne S. Tsao, (unknown), Jeremy Cetnar, Boris Sepesi, Daniel R. Gomez, John Wrangle, George R. Simon, Frank E. Mott, Richard D. Hall, Rafael Santana-Dávila, Marianna Koczywas, Mary W. Redman, Karen Kelly	7
9	MO01.12 Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy 2021 ·Journal of Thoracic Oncology ·(unknown), (unknown), Patrick Young, (unknown), (unknown), Ryan D. Gentzler, Wendy M. Novicoff, Linda W. Martin, Richard D. Hall	3
10	Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use 2021 ·SHILAP Revista de lepidopterología ·Sean C. Dougherty, (unknown), Richard D. Hall	8
11	MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma 2021 ·Frontiers in Oncology ·(unknown), Nolan A. Wages, Patrick A. Grant, P. Todd Stukenberg, Ryan D. Gentzler, Richard D. Hall, Wallace Akerley, Thomas K. Varghese, Susanne M. Arnold, Terence M. Williams, Vincenzo Coppola, David R. Jones, David Auble, Marty W. Mayo	8
12	Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases 2020 ·Journal of Neuro-Oncology ·Sunil W. Dutta, Marie Mack, Eric Aliotta, (unknown), (unknown), James M. Larner, Camilo E. Fadul, Richard D. Hall, Ryan D. Gentzler, Jason P. Sheehan	9
13	Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation 2020 ·The Oncologist ·Patricia J. Hollen, Richard J. Gralla, Ryan D. Gentzler, Richard D. Hall, (unknown), Haiying Cheng, Balázs Halmos, (unknown), (unknown), Ivora Hinton, Geoffrey R. Weiss, Jeffrey Crawford, Jane Cerise, Martin Lesser	2
14	A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients 2019 ·Leukemia & lymphoma ·Robert Weinkove, (unknown), Catherine Wood, (unknown), John Carter, Richard D. Hall, Mark Weatherall, Richard Beasley, Paul J. Young	3
15	Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Daniel Reed, Richard D. Hall, Ryan D. Gentzler, (unknown), Michael G. Douvas, Craig A. Portell	9
16	P3.01-09 Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC 2018 ·Journal of Thoracic Oncology ·Jacqueline T. Brown, (unknown), Margaret E. Moore, A. R. Moore, (unknown), Ryan D. Gentzler, Rajesh Balkrishnan, Richard D. Hall	1
17	Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). 2015 ·PubMed Central ·Richard D. Hall, Tri Minh Le, Daniel Haggstrom, Ryan D. Gentzler	86
18	Three-Dimensional Culture of Mouse Renal Carcinoma Cells in Agarose Macrobeads Selects for a Subpopulation of Cells with Cancer Stem Cell or Cancer Progenitor Properties 2011 ·Cancer Research ·Blair H. Smith, Lawrence S. Gazda, (unknown), (unknown), (unknown), Daniel M. Levine, Thomas S. Parker, (unknown), (unknown), (unknown), (unknown), (unknown), Carlos Cordon‐Cardo, Richard D. Hall, Bruce R. Gordon, (unknown), Kurt H. Stenzel, Albert L. Rubin	43
19	Streptozotocin is responsible for the induction and progression of renal tumorigenesis in diabetic Wistar-Furth rats treated with insulin or transplanted with agarose encapsulated porcine islets 2011 ·Islets ·(unknown), Lawrence S. Gazda, Richard D. Hall, Blair H. Smith	11
20	Design and initial testing of an outer rotating segmented rotor switched reluctance machine for an aero-engine shaft-line-embedded starter/generator 2005 ·Richard D. Hall, A.G. Jack, B.C. Mecrow, A.J. Mitcham	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact